Navigation Links
The Coming of Biotech Generic Pharmaceuticals



Unfortunately, the NCI today is a very large bureaucracy whose goal is the discovery and development of new therapies but not the commercialization of such therapy. As such, the NCI process is very slow.



Given the NCIs role in developing and funding the early stage development of many cancer drugs and the governments concern about the rising cost of medicines, it is ......

Full article >>>
'"/>

Source:wistechnology.com By Michael Rosen 01/26/04


Page: 1 2 3 4

Related biology technology :

1. Social engineering - Coming to an IT ship near you?
2. Biotech officials praise focus of new venture fund
3. Biotech executive books a career flight thats closer to home
4. Gala Biotech among companies sold for $3.3 billion
5. Biotech with Madison ties raises $21M in capital
6. Biotech firm uses live heart tissue in drug screens
7. Biotech talent drew venture-funded firm to Madison
8. Biotech firm has strokes, Alzheimers in its sights
9. 42 days until the 2006 Olympics of Biotechnology in Chicago
10. Biotech crops gaining acceptance, but their full promise has yet to be fulfilled
11. Biotech leads list of top U.S. companies to work for
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The Coming Biotech Generic Pharmaceuticals

Breaking Biology Technology:Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2
Other Biology Technology:Covaris Installed Instrument Base Reaches 500 Units 2Shasta Regional Medical Center Awarded Full Accreditation from the Joint Commission 2Shasta Regional Medical Center Awarded Full Accreditation from the Joint Commission 3Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 2Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 3Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 4Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 5Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 6Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 7Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 8Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 9Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 10Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 11Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 12Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 13Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 14Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 15Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 16Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 17